Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
Open Access
- 20 September 2026
- journal article
- review article
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Abstract
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resiKeywords
Funding Information
- Postdoctoral Fellowship Program of CPSF (BX20240428)
- The Scientific Research Project of Hunan Provincial Health (No. 20230957)
- Natural Science Foundation of Hunan Province (No. 2025JJ60604)
- National Science and Technology Major Project (2023ZD0506105)
- Beijing Huakang Public Welfare Foundation (EXZL-GX-040)
- Beijing KeChuang Medical Development Foundation (KC2023-JX-0186-RQ059)
- Beijing Life Oasis Public Welfare Service Center (BH004506)
This publication has 244 references indexed in Scilit:
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunityBlood, 2010
- CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune SuppressionCancer Research, 2010
- Foxp3+natural regulatory T cells preferentially form aggregates on dendritic cellsin vitroand actively inhibit their maturationProceedings of the National Academy of Sciences, 2008
- Adaptive immunity maintains occult cancer in an equilibrium stateNature, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature, 2001
- HLA-E binds to natural killer cell receptors CD94/NKG2A, B and CNature, 1998
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyNature, 1986